Quick Answer
TENAX THERAPEUTICS, INC. reported Research And Development Expense of $32.67 million for the year ending 2025.
- TENAX THERAPEUTICS, INC. showed an increase of +157.1% in Research And Development Expense from 2024 to 2025.
- This data is from TENAX THERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on March 10, 2026.
- XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2011: $488.6 thousand | Q1 2012: $599.9 thousand | Q3 2012: $637.3 thousand | Q4 2012: $604.6 thousand | Q1 2013: $369.4 thousand | Q3 2013: $772.9 thousand | Q4 2013: $748.6 thousand | Q1 2014: $689.7 thousand | Q3 2014: $966.5 thousand | Q4 2014: $2.56 million | Q1 2015: $1.23 million | Q1 2015: $1.58 million | Q2 2015: $1.95 million | Q3 2015: $1.75 million | Q3 2015: $1.68 million | Q4 2015: $2.52 million | Q1 2016: $3.94 million | Q2 2016: -$3.43 million | Q3 2016: -$3.23 million | Q1 2017: -$2.05 million | Q2 2017: -$1.22 million | Q3 2017: -$254.0 thousand | Q1 2018: -$58.6 thousand | Q2 2018: -$311.2 thousand | Q3 2018: -$362.6 thousand | Q1 2019: -$482.8 thousand | Q2 2019: -$649.3 thousand | Q3 2019: -$917.0 thousand | Q1 2020: -$1.34 million | Q2 2020: $1.27 million | Q3 2020: $1.05 million | Q1 2021: $22.38 million | Q2 2021: $693.2 thousand | Q3 2021: $1.16 million | Q1 2022: $1.18 million | Q2 2022: $1.52 million | Q3 2022: $1.54 million | Q1 2023: $265.7 thousand | Q2 2023: $197.9 thousand | Q3 2023: $1.07 million | Q1 2024: $2.68 million | Q2 2024: $2.33 million | Q3 2024: $3.11 million | Q1 2025: $5.68 million | Q2 2025: $6.12 million | Q3 2025: $10.33 million.
- Over the full 15 years of available data (2011 to 2025), TENAX THERAPEUTICS, INC.'s Research And Development Expense has grown by 1,118.3%.
- Historical annual values: Fiscal year 2025: $32.67 million | Fiscal year 2024: $12.71 million | Fiscal year 2023: $3.23 million | Fiscal year 2022: $5.38 million | Fiscal year 2021: $25.15 million | Fiscal year 2020: $4.56 million | Fiscal year 2019: $3.47 million | Fiscal year 2018: $1.24 million | Fiscal year 2017: $3.53 million | Fiscal year 2016: $13.14 million | Fiscal year 2015: $6.66 million | Fiscal year 2014: $3.00 million | Fiscal year 2013: $2.46 million | Fiscal year 2012: $2.46 million | Fiscal year 2011: $2.68 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: